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SecretionPlatelets store and secrete the chemokine stromal cell-derived factor (SDF)-1α upon platelet activation, but the
ability of platelet-derived SDF-1α to signal in an autocrine/paracrine manner mediating functional platelet
responses relevant to thrombosis and haemostasis is unknown. We sought to explore the role of platelet-
derived SDF-1α and its receptors, CXCR4 and CXCR7 in facilitating platelet activation and determine the
mechanism facilitating SDF-1α-mediated regulation of platelet function. Using human washed platelets,
CXCR4 inhibition, but not CXCR7 blockade signiﬁcantly abrogated collagen-mediated platelet aggregation,
dense granule secretion and thromboxane (Tx) A2 production. Time-dependent release of SDF-1α from
collagen-activated platelets supports a functional role for SDF-1α in this regard. Using an in vitro whole blood
perfusion assay, collagen-induced thrombus formation was substantially reduced with CXCR4 inhibition. In
washed platelets, recombinant SDF-1α in the range of 20–100 ng/mL−1 could signiﬁcantly enhance platelet ag-
gregation responses to a threshold concentration of collagen. These enhancements were completely dependent
on CXCR4, but not CXCR7, which triggered TxA2 production and dense granule secretion. Rises in cAMP were
signiﬁcantly blunted by SDF-1α, which could also enhance collagen-mediated Ca(2+) mobilisation, both of
which were mediated by CXCR4. This potentiating effect of SDF-1α primarily required TxA2 signalling acting
upstream of dense granule secretion, whereas blockade of ADP signalling could only partially attenuate SDF-
1α-induced platelet activation. Therefore, this study supports a potentially novel autocrine/paracrine role for
platelet-derived SDF-1α during thrombosis and haemostasis, through a predominantly TxA2-dependent and
ADP-independent pathway.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Platelet activation relevant to thrombosis and haemostasis is a ﬁnely
coordinated process, involving a complex interplay of subendothelial
matrix proteins (collagen, ﬁbrinogen, vWF), localized thrombin and
platelet-derived factors, in particular the secondary mediators, ADP
and thromboxane (Tx) A2, which culminate to regulate platelet signal-
ling responses following vessel damage [1]. Moreover, numerous
other bioactive molecules are present in the bloodstream or released
from activated platelets, with the ability to potentiate or prime platelet
activation and it's believed that these molecules pose a substantial risk
to pathological thrombus formationwithout being signiﬁcantly relevant; CXCR4, CXC chemokine recep-
telet-rich plasma; TxA2, throm-
aglandin E1; AR-C-66096, AR-C.
harmacology, Medical Sciences
Kingdom. Tel.: +44 117 331
. This is an open access article underto primary haemostasis, thus offering potential therapeutic avenues for
targeting thrombotic disorders [2–4].
Despite being classically known for their chemotactic roles in
leukocyte recruitment and inﬂammatory responses, chemokines
represent an additional layer of complexity to the array of known plate-
let agonists. Platelets express a variety of CC and CXC chemokines and
while the majority of these chemokines can support non-conventional
aspects of platelet function (i.e. leukocyte recruitment, tissue regenera-
tion) [5], certain chemokines were identiﬁed that could induce platelet
activation. Macrophage-derived chemokine (MDC, CCL22) and thymus
and activation-regulated chemokine (TARC, CCL17) are two CC chemo-
kine receptor 4 (CCR4) ligands, which along with stromal cell-derived
factor-1α (SDF-1α, CXCL12) were all shown to induce aggregation
in platelet-rich plasma (PRP) and potentiate platelet responses to
physiological agonists, ADP and thrombin [6–10]. More recently, the
chemokine's CXCL16 and CX3CL1 (fractalkine) were also demonstrated
to trigger platelet activation [11,12]. Notably, early evidence suggested
that platelets did not express these speciﬁc chemokines and it
was proposed that other vascular sources, including macrophages,the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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plaque rupture, could provide localized concentrations sufﬁcient to
potentiate platelet responses [6,9].
Importantly, evidence in recent years has conclusively shown that
platelets express and release functional SDF-1α upon activation,where-
as evidence supporting the release of platelet-derivedMDC and TARC is
less established [13–15]. Studies have demonstrated novel roles for
platelet-derived SDF-1α in recruiting CD34+ progenitor cells to arterial
thrombi and supporting their differentiation to endothelial progenitor
cells in vivo, to facilitate vascular remodelling and repair [16,17].
More recently, SDF-1α from activated platelets was demonstrated to
be crucial for the transformation of circulatingmonocytes into multipo-
tential cells with the capacity to differentiate into mesenchymal and
endothelial lineages [18]. Despite these insights, the possibility of
platelet-derived SDF-1α exerting autocrine/paracrine signalling effects
regulating platelet activation relevant to thrombosis or haemostasis, in
a manner similar to the classical secondary mediators ADP or TxA2,
has not been explored. Moreover, the mechanisms by which SDF-1α
mediates enhancements of platelet function are poorly deﬁned.
SDF-1α was originally believed to signal exclusively via the Gαi-
coupled G-protein-coupled receptor (GPCR), CXC chemokine receptor
type 4 (CXCR4), but more recent studies identiﬁed CXCR7 as a higher
afﬁnity receptor for SDF-1α [19–22]. Like CXCR4, CXCR7 possesses all
the canonical components of GPCRs, but it is unable to activate
heterotrimeric G proteins, so that themechanismsmediating activation
of intracellular signals remain controversial [23–25]. CXCR7 is believed
to operate as a decoy receptor, which can internalize bound SDF-1α
to regulate SDF-1α gradients necessary for optimal signals via CXCR4
[26]. Additionally, both receptors can heterodimerise to regulate SDF-
1α-mediated functions [27]. Importantly, both receptors are expressed
on the platelet surface and while CXCR4 appears functional, the rele-
vance of CXCR7 to platelet physiology is only starting to be elucidated
[6,28–30].
With this study, we sought to determine if SDF-1α plays a signiﬁcant
autocrine/paracrine signalling role regulating human platelet function
through its two cognate receptors and to address the mechanism of
SDF-1α-mediated regulation of platelet activation with relevance to
ADP and TxA2 signalling. Since the annucleate platelet is not amenable
to genetic manipulation, we used a pharmacological inhibitor and
blocking antibody approach to delineate novel signalling roles for target
proteins. Our ﬁndings demonstrate that blocking CXCR4, but not CXCR7,
signiﬁcantly reduced collagen-mediated platelet aggregation, dense
granule secretion and TxA2 production. Consistently, in vitro collagen-
induced thrombus formation required CXCR4-dependent signalling. To
support a synergistic signalling mechanism between collagen and
SDF-1α, co-stimulation experiments revealed that SDF-1α, via CXCR4,
could substantially enhance platelet activation to threshold concentra-
tions of collagen, through an ampliﬁcation pathway which is primarily
TxA2-dependent, but ADP-independent.
2. Materials and methods
2.1. Materials
Platelet agonists used were ﬁbrillar HORM® Collagen (Type I) of
equine tendon (Nycomed, Munich, Germany) and human recombinant
SDF-1α (R&D Systems Europe, Abingdon, UK). Pharmacological
inhibitors; AMD3100 octahydrochloride (CXCR4), MRS-2279 (P2Y1),
and AR-C66096 (P2Y12 — abbreviated AR-C) were from R&D Systems
and indomethacin (cyclooxygenase) was from Sigma-Aldrich (Poole,
UK). All inhibitors used were dissolved in modiﬁed HEPES-Tyrodes,
with the exception of indomethacin, which was dissolved in DMSO
(vehicle conc. was 0.1%). Anti-CXCR7 blocking antibody (Clone 11G8)
and isotype control (Mouse IgG1) were from R&D Systems and anti-
CD32/FcγRIIA (Clone IV.3) was from StemCell Technologies (Grenoble,
France). D-Phenylalanyl-L-propyl-L-arginine chloromethyl ketone(PPACK) was from Calbiochem (Merck Chemicals, Nottingham, UK)
and heparin was from Sigma-Aldrich. Unless stated, all other reagents
used were from Sigma-Aldrich.
2.2. Human platelet preparation
Venous human blood from healthy, drug-free volunteers was drawn
in 0.4% trisodium citrate (v/v) in accordance with the local ethics
committee and informed consent. In brief, citrated blood was acidiﬁed
with 12.5% (v/v) acid citrate dextrose (85 mM trisodium citrate,
71 mM citric acid, 111 mM glucose) and centrifuged at 190 ×g for
17 min. PRP was removed and centrifuged at 650 ×g for 10 min in the
presence of 140 nM prostaglandin (PG) E1 and 0.02 U mL−1 apyrase
(Grade VII, Sigma). The resulting platelet pellet was resuspended at the
required density in modiﬁed HEPES-Tyrode's buffer (10 mM HEPES,
145 mMNaCL, 1 mMMgCl2, 3 mM KCL, 5 mMGlucose, pH 7.3) contain-
ing 0.02 U mL−1 apyrase.
2.3. Lumi-aggregometry — platelet aggregation and ATP secretion
Simultaneous monitoring of platelet aggregation and ATP secretion
was performed at 37 °Cwith constant stirring (1000 rpm) in aChronolog
700 aggregometer (Chronolog, Havertown, PA, USA). For all experiments
involvingpharmacological inhibitors, platelets (2 × 108mL−1)were pre-
treated with vehicle control or inhibitors for 10 min. Also, for
experiments involving functional blockade of platelet CXCR7, platelets
were pre-incubated for 10 min with 10 μg/mL−1 IV.3 prior to a 10 min
incubation with 10 μg/mL−1 anti-CXCR7 (11G8) or IgG1 control to
prevent non-speciﬁc platelet activation via the FcγRIIA receptor. Before
agonist stimulation, 5 μL of luciferin-luciferase (Chronolog) was added.
Post aggregation, 1 nM ATP standard was added as a reference value
for quantiﬁcation of secreted ATP. Data analysis was performed with
Aggro/Link5 software (Chronolog).
2.4. Measurement of TxA2 production
To assess TxA2 levels, the stable metabolite TxB2 was analysed using
a commercial ELISA kit (Enzo Life Sciences, Exeter, UK). Brieﬂy, activat-
ed platelet samples (from aggregation reactions) were quenched at
5 min with 5 mM EDTA and 200 μM indomethacin to inhibit further
TxA2 formation. Samples were centrifuged for 4 min at 12,000 ×g,
with the supernatant removed and stored at −80 °C for subsequent
TxB2 analysis according to manufacturer's instructions.
2.5. SDF-1α ELISA
Tomonitor soluble SDF-1α release, washed platelets (4 × 108mL−1)
were stimulated under aggregating conditions for indicated times.
Samples were immediately transferred to an eppendorf containing
280 nM PGE1 (ﬁnal conc.) and subjected to 2 × pulse centrifugation
steps (15 s at 12,000 ×g), with the ﬁnal releasate stored at−80 °C for
subsequent analysis by SDF-1α ELISA as permanufacturer's instructions
(R&D Systems).
2.6. cAMP ELISA
For quantiﬁcation of cyclic adenosine monophosphate (cAMP),
washed platelets (4 × 108 mL−1) were pre-treated with inhibitors and
stimulated with 1 μM PGE1 in the absence or presence of SDF-1α for
5 min at 37 °C. cAMP accumulation was terminated by the addition
lysis buffer (0.5% TritonX-100) containing 0.1 M HCL to stop endoge-
nous phosphodiesterase activity for 30 min at room temperature.
Samples were clariﬁed by centrifugation at 12,000 × g for 5 min
with the supernatant stored for subsequent analysis by cAMP ELISA
according to manufacturer's instructions (Enzo Life Sciences).
Fig. 1. Collagen-induced SDF-1α release and regulation of platelet aggregation by CXCR4. A–B, Washed platelets (2 × 108/mL−1) were pre-treated with vehicle control or inhibitors;
(A) 100 nM AMD3100 (CXCR4) and (B) 10 μg/mL−1 11G8 (CXCR7) or IgG1 control in the presence of 10 μg/mL−1 IV.3 and monitored for platelet aggregation using a range of collagen
concentrations. Representative aggregation traces (A–Bi) and quantiﬁed area under the curve analysis (A–Bii) are shown. Data are mean ± SEM, n = 6, *** P b 0.001 vs. vehicle, Two-
way ANOVA with Bonferroni post-hoc analysis. C) Washed platelets (4 × 108 mL−1) were stimulated with 2.5 μg/mL−1 collagen for indicated time points under aggregating conditions,
with subsequent analysis of platelet releasate by SDF-1α ELISA. Data are mean ± SEM, n = 4, **P b 0.01 vs. basal, One-way ANOVA with Dunnett's multiple comparison test.
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Ca(2+) measurement was performed as previously described [31].2.8. In vitro thrombus formation
Analysis of thrombus formation was performed using an Ibidi®
μ-Slide VI0.1 ﬂow chamber (Thistle Scientiﬁc Ltd, Glasgow, UK) connect-
ed to aHarvardApparatus syringe pump (Kent, UK). Prior towhole blood
perfusion, the Ibidi μ-slide channels were coated with 50 μg/mL−1
ﬁbrillar collagen for 2 h at room temperature and blocked in 2% fattyacid free BSA (Sigma) overnight at 4 °C. Channels were ﬂushed with
modiﬁed HEPES-Tyrodes immediately prior to whole blood perfusion.
Anti-coagulated blood drawn in 40 μM PPACK and 2 U mL−1 heparin
was loaded with 2 μM DiOC6 (Enzo Life Sciences) in the presence of
vehicle control or 100 nM AMD3100 for 10 min. Labelled blood was
then perfused at a constant shear rate of 1000 s−1 for 6 min, followed
by a 4 min wash/ﬁxation step in modiﬁed HEPES-Tyrodes containing
4% para-formaldehyde at a similar shear rate. Images of platelet thrombi
were captured through a 40× oil immersion objective on Leica DM IRE2
inverted epiﬂuorescent microscope attached to a Leica TCS-SP2-AOBS
confocal LSM. Five randomly chosen ﬁelds of view were analysed per
sample with a z-axis interval of 1 μmper confocal section. Quantiﬁcation
Fig. 2. Regulation of collagen-mediated dense granule secretion and TxA2 production by CXCR4.Washed platelets (2 × 108/mL−1) were pre-treatedwith vehicle control or inhibitors; (A,
Ci) 100 nM AMD3100 (CXCR4) and (B, Cii) 10 μg/mL−1 11G8 (CXCR7) or IgG1 control in the presence of 10 μg/mL−1 IV.3 and stimulated with increasing concentrations of collagen. ATP
release from dense granules (A, B) was assessed by lumi-aggregometry, while TxA2 production (C) was monitored by a TxB2 ELISA using releasates generated from samples in A–B.
Representative secretion traces (A–Bi) and peak ATP release values (nmoL ATP/108 platelets, A–Bii) are shown. Data are mean ± SEM, n = 4, *P b 0.05 vs. vehicle, Two-way ANOVA
with Bonferroni post-hoc analysis.
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using Volocity® 6.1.1 Quantitation software (Perkin Elmer Inc., San
Jose, CA, USA).2.9. Statistical analysis
All data was analysed using GraphPad Prism 5 software (GraphPad
Software Inc., San Diego, CA, USA). Quantiﬁed data are presented as
mean ± SEM with the indicated number of independent observations.
A value of *P b 0.05 was considered statistically signiﬁcant and was
determined using either a paired Student's t-test or one- and two-way
ANOVA with Dunnett's or Bonferroni post hoc test for multiple
comparison.3. Results
3.1. Collagen-induced SDF-1α release and regulation of platelet aggregation
by CXCR4
While it is well established that platelets store SDF-1α and
exogenously added SDF-1α can induce platelet aggregation in PRP, the
possibility of platelet-derived SDF-1α exerting autocrine/paracrine
effects on platelet activation is unexplored. To investigate this, we used
the pharmacological inhibitor, AMD3100 [32] and blocking antibody
11G8 [33], to target the two known receptors for SDF-1α, CXCR4 and
CXCR7, respectively and assessed platelet responses to the physiological
agonist collagen. Blocking the CXCR4 receptor yielded a signiﬁcant re-
duction in platelet aggregation responses to intermediate but not high
Fig. 3. Collagen-induced thrombus formation requires CXCR4-dependent signalling. PPACK- (40 μM) and Heparin- (2 U/mL−1) anticoagulatedwhole blood labelledwith 2 μMDiOC6was
pre-treatedwith vehicle control or 100 nMAMD3100 and perfused over a collagen-coated surface for 6min at a constant shear of 1000 s−1. Sampleswere subsequentlywashed and ﬁxed
in modiﬁed HEPES-Tyrodes containing 4% paraformaldehyde. Representative confocal images at the collagen surface (z position = 0 μm) with 4 μm increments, as indicated, are shown
along with quantitative analysis of platelet thrombus coverage (%) and volume (μm3) (Ai–iii). Data are mean ± SEM, n = 4, *P b 0.05 vs. vehicle, two-tailed paired Student's t-test.
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Targeting CXCR7 with 11G8 did not produce any apparent, functional
impairment of aggregation responses across the range of collagen
doses (Fig.1Bi–ii). To support a potential role for platelet-derived SDF-
1α in regulating CXCR4-mediated regulation of collagen responses, we
monitored the release of SDF-1α under similar aggregating conditions
to collagen. Analysis of SDF-1α release kinetics by ELISA revealed sub-
stantial increases in soluble SDF-1α compared to basal levels, which
were statistically signiﬁcant between 2–5 min post stimulation (Fig. 1C).3.2. Regulation of collagen-induced dense granule secretion and TxA2
production by CXCR4
To monitor dense granule secretion, we assessed ATP release by
lumi-aggregometry, which demonstrated that CXCR4 inhibition
induced a signiﬁcant reduction in peak ATP secretion values at inter-
mediate collagen concentrations, but not with higher concentrationsof collagen (Fig. 2Ai–ii). However, no obvious changes in the rate of
ATP secretion were observed. Similarly, blocking CXCR4 leads to a
signiﬁcant reduction in total TxA2 levels, whichwas only apparent at in-
termediate collagen concentrations (Fig.2). Consistent with the lack of
effect on collagen-induced aggregation, blockade of CXCR7 signalling
with 11G8 did reveal any signiﬁcant changes in ATP secretion or TxA2
responses to collagen (Fig.2Bi–ii, Cii).3.3. Collagen-induced thrombus formation requires CXCR4-dependent
signalling
Considering the defect in collagen-induced platelet activation with
CXCR4 inhibition, we sought to investigate the role for this receptor
on thrombus formation over collagen at arterial shear. We utilized
confocal microscopy to facilitate assessment of thrombus volume and
thrombus coverage at the collagen surface. Notably, therewas no signif-
icant difference in percentage platelet coverage of the collagen surface
Fig. 4. SDF-1α-mediated enhancement of platelet activation by CXCR4. A,Washed platelets (2 × 108/mL−1) were co-stimulatedwith a threshold concentration of collagen (0.5 μg/mL−1)
and increasing concentrations of SDF-1α, and monitored for platelet aggregation. A representative trace (Ai) and quantiﬁed area under the curve analysis (Aii) are shown. Data are
mean ± SEM, n = 10, **P b 0.01, ***P b 0.001 vs vehicle, One-way ANOVA with Dunnett's multiple comparison test. B–D). Similarly, washed platelets (2 × 108/mL−1) were pre-treated
with vehicle control or inhibitors; 100 nMAMD3100 (CXCR4) and 10 μg/mL−1 11G8 (CXCR7) or IgG1 control in the presence of 10 μg/mL−1 IV.3 and co-stimulatedwith 0.5 μg/mL−1 col-
lagen and 100 ng/mL−1 SDF-1α. Platelet aggregation with area under the curve analysis (B) and peak ATP secretion (C) were assessed by lumi-aggregometry, with the releasates from
aggregated samples analysed for TxB2 (D). Data are mean ± SEM, n = 4 (n = 6 for B), *P b 0.05, **P b 0.01, ***P b 0.001, One-way ANOVA with Dunnett's multiple comparison test.
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(Fig. 3ii). However, as shown by representative end-point images at
different z planes and the subsequent analysis of thrombus volume,
inhibition of CXCR4 signiﬁcantly reduced thrombus accumulation
(Fig. 3i, iii). The data suggest that CXCR4 contributes to the thrombus
build up, but not to the initial adhesion of platelets to the collagen-
coated surface.
3.4. SDF-1α-mediated enhancement of platelet activation by CXCR4
SDF-1α alone did not induce platelet activation in washed platelets
(data not shown), which is comparable with previous reports and stud-
ies using agonists targeting other Gαi-coupled receptors [9,34]. Toaddress enhancements of platelet function attributable to SDF-1α in a
washed platelet system, platelets were co-stimulated with a threshold
concentration of collagen and recombinant SDF-1α, which would
also allow further investigation into the relative roles for CXCR4 and
CXCR7 in this regard. SDF-1α dose-dependently enhanced the aggrega-
tion response to 0.5 μg/mL−1 collagen, with signiﬁcant enhancements
observed within the range of 20–100 ng/mL−1 SDF-1α (Fig. 4Ai–ii).
Subsequent experiments conﬁrmed that SDF-1α-mediated enhance-
ments of platelet aggregation (Fig. 4B), dense granule secretion
(Fig. 4C) and TxA2 production (Fig. 4D) in the presence of low dose
collagen, were signiﬁcantly attenuated by pre-treatment with the
CXCR4 inhibitor AMD3100, whereas blocking CXCR7 did not affect any
of these responses.
Fig. 5. Regulation of cAMP and Ca(2+) signalling by SDF-1α. A, Washed platelets (4 × 108/mL−1) were pre-treated with vehicle control or 100 nM AMD3100 and then stimulated with
0.7% EtoH (ﬁnal conc.— carrier for PGE1) or 1 μMPGE1 in the absence or presence of 100 ng/mL−1 SDF-1α. Samples were lysed and analyzed for total cAMP levels (pmol/mL−1) by ELISA.
Data are mean ± SEM, n = 4, **P b 0.01, ***P b 0.001, One-way ANOVA with Dunnett's multiple comparison test. B, Washed platelets (1 × 108/mL−1) were loaded with Fura2-AM and
stimulated with 100 ng/mL−1 SDF-1α alone (Bi) or co-stimulated with 2.5 μg/mL−1 collagen and 100 ng/mL−1 SDF-1α (or vehicle) in the absence or presence of 100 nM AMD3100 to
monitor changes in intracellular calcium responses (Bii). Traces shown are representative of 4 independent experiments.
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Seeing as both CXCR4 and CXCR7 are reported to be Gαi-coupled
GPCRs,we sought to investigate the role of each receptor on cAMP levels
in response to SDF-1α stimulation. Similar to the ﬁndings by Kowalska
et al. [9], SDF-1α could signiﬁcantly reduce the rise in cAMP evoked by
PGE1 stimulation of prostaglandin receptors. Moreover, this effect was
signiﬁcantly inhibited by CXCR4 inhibition (Fig. 5A), while blocking
CXCR7 had no effect (Fig. 5A). Importantly, blockade of the Gi-coupled
P2Y12 receptor with AR-C did not interfere with SDF-1α-mediated
changes in cAMP, ruling out the possibility of secreted ADP facilitating
this response (data not shown). Discrepancies regarding the ability of
SDF-1α to evoke rises in intracellular Ca(2+) exist [6,8]. In our hands,
SDF-1α alone could not induce alterations in cytosolic Ca(2+), but
when co-stimulated with collagen, it produced a profound rise in the
rate of the Ca(2+) signal that was substantially attenuated by CXCR4
inhibition (Fig. 5Bi–ii).3.6. SDF-1α-mediated enhancement of platelet activation is primarily TxA2-
dependent and ADP-independent
To explore the mechanism(s) mediating SDF-1α-induced enhance-
ments of platelet activation, platelets were pre-treated with or without
indomethacin or the ADP receptor antagonists, AR-C and MRS 2279,
to ablate TxA2- and ADP-dependent signalling, respectively, and
then co-stimulated with threshold concentrations of collagen and
100 ng/mL−1 SDF-1α. Blocking TxA2 signalling with indomethacin
(Fig. 6C) substantially abrogated the enhanced aggregation and ATP
secretion responses to SDF-1α, although the aggregation response was
not completely suppressed (Fig. 6Ai, iii, B). Inhibition of ADP signalling
revealed that SDF-1α could still induce signiﬁcant enhancements of
platelet aggregation (Fig. 6Aii–iii), ATP secretion (Fig. 6B) and TxA2
production (Fig. 6C), although aggregation responses were not fully
recovered (Fig. 6Aiii).4. Discussion
It is clear that there are multiple mechanisms controlling platelet
function which dictates the extent of the response necessary to control
bleeding or facilitate thrombus growth leading to coronary and cerebro-
vascular ischemic events. Currently, the most prevalent anti-platelet
therapies prophylactically administered to cardiovascular disease
risk patients involve targeting TxA2 andADP, via aspirin and clopidogrel,
respectively. Despite proven effectiveness, these antiplatelet agents
have experienced issues of non-responsiveness, while attempts to
induce more potent inhibition of platelet function have been associated
with bleeding complications [35–37]. With this study, we aimed to
explore the role of platelet-derived SDF-1α as a potentially novel, auto-
crine/paracrinemediator of platelet function in response to the primary
platelet agonist collagen and to determine the mechanism through
which SDF-1α exerts its enhancing effects on platelet activation.
To exclude a potential role for plasma-derived SDF-1α, our initial
studies in washed platelets revealed an important role for the SDF-
1α receptor, CXCR4, but not CXCR7 in regulating platelet aggregation
and activation responses to intermediate concentrations of collagen.
Notably, TxA2 production and dense granule secretion were signiﬁ-
cantly reduced by CXCR4 inhibition in response to intermediate
collagen doses, providing a mechanistic basis for the defect in plate-
let aggregation. Indeed, platelet responses to collagen are primarily
dependent on signalling via secondary mediators, TxA2 and ADP
[38]. To support a role for SDF-1α in this regard, we demonstrate
the time-dependent release of SDF-1α release under similar aggre-
gating conditions, in line with previous studies which show SDF-1α
release under different conditions [16,29]. Moreover, in a separate
experiment, it was observed that only 36% of recombinant SDF-1α
could be recovered from a platelet suspension when compared to a
buffer alone sample, suggesting that the ELISA values somewhat
underestimate the actual released values for SDF-1α (data not
shown). Nonetheless, this supports a model that SDF-1α released
from activated platelets can act back on itself, consistent with the
Fig. 6. SDF-1α-mediated enhancement of platelet activation is primarily TxA2-dependent and ADP-independent. Washed platelets (2 × 108/mL−1) were pre-treated with vehicle control
or inhibitors; 10 μM indomethacin (cyclooxygenase) or 1 μM AR-C and 10 μM MRS 2279 (P2Y1 and P2Y12, respectively) and co-stimulated with threshold doses of collagen
and 100 ng/mL−1 SDF-1α. For inhibitor treated samples, platelets were stimulated with 2 μg/mL−1 collagen (vs. 0.5 μg/mL−1 in non-inhibitor treated samples) to induce threshold ag-
gregation responses that were comparable to non-inhibitor treated samples. * in Ai–ii denotes different collagen concentrations. Platelet aggregation with representative traces (Ai–ii),
area under the curve analysis (Aiii) and peak ATP secretion (B) were assessed by lumi-aggregometry, with the releasates from aggregated samples analysed for TxB2 (C). Data are
mean ± SEM, n = 5, non-signiﬁcant (ns), *P b 0.05, **P b 0.01, ***P b 0.001 vs. vehicle, Two-way ANOVA with Bonferroni post-hoc analysis.
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under both resting and activated conditions [39].
Considering the defect in platelet responses to collagen following
CXCR4 inhibition, we expanded our observations to an in vitro whole
blood perfusion assay over a collagen-coated surface tomonitor throm-
bus formation at arterial shear. Two-dimensional end-point analysis
of platelet deposition at the collagen surface revealed no signiﬁcant
difference in thrombus coverage, but subsequent three-dimensional
analysis of thrombus volume revealed a signiﬁcant reduction in the
presence of the CXCR4 inhibitor, AMD3100. These observations support
a model that the initial phase of platelet adhesion to collagen is pre-
served, but the secondary, expansion phase involving the recruitment
of additional platelets to the growing thrombus is abrogated, which is
similar to the thrombus phenotype observed in the presence of aspirin
or P2Y12 inhibitors [40].Our evidence supports a functional role for the CXCR4 receptor in
the secondary phase of platelet activation. However, despite the initial
belief that SDF-1α and CXCR4 were a monogamous ligand-receptor
pair, subsequent studies identiﬁed alternative ligands for CXCR4. The
ubiquitously expressed chemokine, macrophage migration inhibition
factor (MIF) was demonstrated as a noncognate ligand of CXCR4 (and
CXCR2), shown to facilitate leukocyte recruitment during inﬂammatory
diseases such as atherosclerosis [41]. Currently, there is no evidence to
suggest that MIF can act as a platelet agonist. On the contrary, bile
salt-dependent lipase (BSDL), which contains structural homology to
the V3 loop of HIV-1 that also binds CXCR4, was shown to regulate
platelet activation via CXCR4 and accumulate at vessel injury sites in
a CXCR4-dependent manner [42]. Moreover, mice deﬁcient in SDF-1α
(or CXCR4) die perinatally due to numerous development defects
excluding an experimental approach involving SDF-1α deﬁcient
45T.G. Walsh et al. / Cellular Signalling 27 (2015) 37–46platelets [43]. This ambiguous nature of CXCR4 ligands makes accurate
inferences about their precise roles under physiological conditions
more challenging and we therefore phrase our ﬁndings in terms of a
‘potential’ role for platelet-derived SDF-1α as an autocrine/paracrine
mediator of platelet function.
To address these limitations, we designed experiments involving
threshold concentrations of collagen and exogenously added SDF-1α
to examine the synergistic contributions of CXCR4 or CXCR7 to SDF-
1α-mediated enhancements of platelet activation. SDF-1α alone did
not induce an aggregation response in washed platelets (data not
shown). However, in combination with low-dose collagen, SDF-1α
could elicit substantial enhancements in platelet aggregation responses,
which were statistically signiﬁcant at doses as low as 20 ng/mL−1
and maximally so within the range of 50–100 ng/mL−1. This SDF-1α-
mediated enhancement of aggregation was almost completely
suppressed with CXCR4 inhibition, whereas blockade of CXCR7 elicited
no apparent effect. Furthermore, elevated TxA2 levels and dense granule
secretion were observed under these conditions, both of which were
regulated by CXCR4.
Gαi-coupled GPCRs signal to inhibit adenylyl cyclase and thereby
downregulate cAMP levels, which is associated with enhanced platelet
aggregation and platelet accumulation in vivo [44,45]. Our investiga-
tions demonstrate that SDF-1α could signiﬁcantly attenuate the rise in
cAMP induced by PGE1, which is consistent with a previous study [9].
Our observations conﬁrm that this inhibitory effect is mediated by
CXCR4, whereas CXCR7 blockade had no effect. This was consistent
with the literature that CXCR7 cannot induce heterotrimeric G-protein
activity and does not couple to signalling events [23]. cAMP is known
to modulate platelet function by interfering with both Ca(2+) entry
and intracellular Ca(2+)mobilisation, which is critical for platelet acti-
vation during thrombosis and haemostasis [46,47]. In our hands, SDF-
1α alone did not induce intracellular Ca(2+) signals, but co-
stimulation with collagen facilitated a rapid, enhanced rate of Ca(2+)
mobilisation, which was substantially ablated with CXCR4 inhibition.
These elevated Ca(2+) signals are critical for activating various sensors
and key regulatory enzymes, including the Ca(2+)-dependent cytosol-
ic phospholipase A2 (cPLA2), which is essential for TxA2 production
through mobilisation of arachidonic acid [48], thereby providing
a possible signalling node through which SDF-1α ampliﬁes TxA2
production.
Notably, we did not observe any functional detriment to platelet-
collagen responses by interfering with CXCR7 function. These results
are not entirely surprising considering that CXCR7 does not activate
Gαi-driven pathways and Ca(2+) mobilisation, unlike CXCR4 [24,49].
Interestingly, Chatterjee and colleagues recently demonstrated
enhanced platelet surface levels of CXCR7 following SDF-1α stimula-
tion, which reduced agonist-induced apoptosis [29]. Since SDF-1α
is known to mediate pro-survival signals, these data suggest a non-
conventional role for CXCR7 in platelets supporting potential regenera-
tive and repair mechanisms following vessel injury, which correlates
with clinical evidence showing enhanced platelet CXCR7 levels in
patients with myocardial infarction [28,50].
The augmented TxA2 and dense granule secretion responses to
collagen in the presence of SDF-1α alluded to a key role for TxA2 or
ADP as secondary mediators of the response to SDF-1α. Subsequently,
we investigated the ability of SDF-1α to enhance platelet aggregation
to collagen in the presence of a cyclooxygenase inhibitor (indometha-
cin) or ADP receptor antagonists, P2Y1 (MRS 2279) and P2Y12 (AR-C).
Blocking TxA2 production with indomethacin signiﬁcantly attenuated
the SDF-1α-induced enhancements of platelet aggregation and ATP
secretion, which also imply that TxA2 generation is upstream of dense
granule secretion. However, in the absence of TxA2, SDF-1α still
exhibited a weak, yet statistically signiﬁcant enhancement of platelet
aggregation compared to non SDF-1α-treated samples, suggesting a
partial TxA2-independent regulation of platelet activation. This ﬁnding
supports previous observations demonstrating that SDF-1α inducedplatelet aggregation in PRP consists of a primary, TxA2-independent
wave of aggregation, followed by a secondary TxA2-dependent wave
[6]. Surprisingly, in the presence of P2Y1 and P2Y12 receptor antagonists,
SDF-1α could still induce profound, statistically signiﬁcant enhance-
ments of aggregation, ATP secretion and TxA2 production. However,
aggregation responses to SDF-1α were not fully recovered in the
absence of ADP signalling implying a subtle, yet functional role for
dense granule secretion facilitating platelet activation by SDF-1α.
Overall, these ﬁndings implicate a predominantly TxA2-dependent
and ADP-independent signalling pathway driving SDF-1α-mediated
responses. Interestingly though, these observations are in contrast to a
study by Borst et al., which revealed that CXCL16-induced platelet
activation is ADP-dependent and TxA2-independent, alluding to diver-
gent signalling networks propagated by chemokines in platelets [11].
From a clinical context, our data highlights potential drawbacks in
currently prescribed anti-platelet therapies, particularly with respect
to P2Y12 antagonism. In vivo studies have clearly demonstrated that
SDF-1α is highly abundant in coronary thrombi during the acute
phase following vessel injury, providing localized concentrations that
not only facilitate progenitor cell recruitment, but may also potentiate
platelet activation responses [16]. Similarly, platelet surface expression
of SDF-1α is enhanced in patients with acute coronary syndrome
and reduced systolic ventricular function [51]. Also pertinent, several
studies have documented elevated plasma SDF-1α levels in different
cancerous and inﬂammatory patient populations [52,53]. Most striking
was the observation that elevated SDF-1α levels (mean value of
10.8 ng/mL−1) were the single predictor of ischemic stroke events
when compared to traditional risk factors such as hypertension,
dyslipidemia and tobacco use [54]. Such continuous exposure of
platelets to elevated levels of plasma SDF-1α, in conjunction with
other blood borne factors would facilitate a priming effect on plate-
lets, thereby exacerbating platelet responses to subsequent stimuli
[2].5. Conclusion
Our study implicates a potentially novel autocrine/paracrine signal-
ling role for platelet-derived SDF-1α acting exclusively via CXCR4,
culminating in enhanced TxA2 production and dense granule secretion
to facilitate thrombus formation. The platelet enhancing effects of
SDF-1α to collagen are primarily driven by TxA2-dependent signalling,
whereas ADP-mediated signalling appears to contribute minimally.
Importantly, we provide sufﬁcient evidence to support a more promi-
nent role for platelet-released SDF-1α in the array of platelet activation
events critical for thrombosis and haemostasis.Conﬂict of interest
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